STOCK TITAN

Roche reports 17.4% passive stake in Freenome

Freenome, Inc. (FRNM) has a significant shareholder group led by Roche entities that jointly report beneficial ownership of a large minority stake in the company.

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Freenome, Inc. (FRNM) has a significant shareholder group led by Roche entities that jointly report beneficial ownership of a large minority stake in the company. Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd (the “Reporting Persons”) have filed a Schedule 13G disclosing their ownership in Freenome’s common stock.

The Reporting Persons report beneficial ownership of 18,692,766 shares of Freenome common stock, representing 17.4% of the class, based on 107,446,814 shares outstanding as of July 20, 2026. Of these, 18,055,686 shares are held of record by Roche Holdings, Inc. and 637,080 shares are held of record by Roche Finance Ltd. The Reporting Persons state they have 0 shares with sole voting or dispositive power and 18,692,766 shares with shared voting and dispositive power.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 18,692,766 shares of common stock Beneficially owned by the Roche reporting group
Percent of class beneficially owned 17.4 % Portion of Freenome common stock reported as owned by the Roche group
Shares held by Roche Holdings, Inc. 18,055,686 shares of common stock Held of record by Roche Holdings, Inc.
Shares held by Roche Finance Ltd 637,080 shares of common stock Held of record by Roche Finance Ltd
Shares outstanding 107,446,814 shares of common stock Freenome shares outstanding as of July 20, 2026
Shared voting power 18,692,766 shares Shares over which the Reporting Persons have shared voting power
Shared dispositive power 18,692,766 shares Shares over which the Reporting Persons have shared dispositive power
Schedule 13G regulatory
"This is filed jointly by Roche Holdings, Inc., Roche Finance Ltd and Roche Holding Ltd"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially own financial
"Roche Finance Ltd may be deemed to beneficially own the shares held by Roche Holdings, Inc."
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting power financial
"Shared Voting Power 18,692,766.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 18,692,766.00"
Joint Filing Agreement regulatory
"A Joint Filing Agreement is attached as Exhibit 99.1."

FAQ

How much of Freenome, Inc. (FRNM) do the Roche entities beneficially own?

The Roche reporting group beneficially owns 18,692,766 shares of Freenome, Inc. common stock, representing 17.4% of the outstanding common shares, based on 107,446,814 shares outstanding as of July 20, 2026.

Which Roche entities are reporting ownership in Freenome, Inc. (FRNM)?

The filing is made jointly by Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd. Roche Holdings, Inc. is a wholly owned subsidiary of Roche Finance Ltd, which in turn is a wholly owned subsidiary of Roche Holding Ltd.

How are the 18,692,766 Freenome (FRNM) shares held by the Roche group allocated?

The reported 18,692,766 shares consist of 18,055,686 shares of Freenome common stock held of record by Roche Holdings, Inc. and 637,080 shares held of record by Roche Finance Ltd.

What voting and dispositive powers do the Roche entities report for their Freenome (FRNM) shares?

The Reporting Persons state they have 0 shares with sole voting power and 18,692,766 shares with shared voting power. They also have 0 shares with sole dispositive power and 18,692,766 shares with shared dispositive power.

What share count did Freenome (FRNM) report as outstanding for this Schedule 13G calculation?

The 17.4% ownership percentage is calculated based on 107,446,814 shares of Freenome’s common stock outstanding as of July 20, 2026, as reported by the company in a Current Report on Form 8-K filed on July 24, 2026.

What type of filing did the Roche entities submit regarding Freenome, Inc. (FRNM)?

They submitted a Schedule 13G, which reports beneficial ownership of Freenome common stock by Roche Holdings, Inc., Roche Finance Ltd, and Roche Holding Ltd, and includes a Joint Filing Agreement as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





35661P100

(CUSIP Number)
07/20/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported in Items 6, 8 and 9 herein consist of (i) 18,055,686 shares of common stock held of record by Roche Holdings, Inc. and (ii) 637,080 shares of common stock held of record by Roche Finance Ltd. The percentage in Item 11 is calculated based upon 107,446,814 shares of the Issuer's common stock outstanding as of July 20, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 24, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported in Items 6, 8 and 9 herein consist of (i) 18,055,686 shares of common stock held of record by Roche Holdings, Inc. and (ii) 637,080 shares of common stock held of record by Roche Finance Ltd. The percentage in Item 11 is calculated based upon 107,446,814 shares of the Issuer's common stock outstanding as of July 20, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 24, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported in Items 6, 8 and 9 herein consist of (i) 18,055,686 shares of common stock held of record by Roche Holdings, Inc. and (ii) 637,080 shares of common stock held of record by Roche Finance Ltd. The percentage in Item 11 is calculated based upon 107,446,814 shares of the Issuer's common stock outstanding as of July 20, 2026, as reported by the Issuer in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 24, 2026.


SCHEDULE 13G



Roche Holdings, Inc.
Signature:/s/ Anjna Mehta
Name/Title:Anjna Mehta, Authorized Signatory
Date:09/01/2026
Roche Finance Ltd
Signature:/s/ Anja Harmeier
Name/Title:Anja Harmeier, Authorized Signatory
Date:09/01/2026
Signature:/s/ Peter Trybus
Name/Title:Peter Trybus, Authorized Signatory
Date:09/01/2026
Roche Holding Ltd
Signature:/s/ Claudia Bockstiegel
Name/Title:Claudia Bockstiegel, Authorized Signatory
Date:09/01/2026
Signature:/s/ Peter Trybus
Name/Title:Peter Trybus, Authorized Signatory
Date:09/01/2026
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement